INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer
02.01.2024 - Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, dosed ... Seite 1
Boca Raton United States Matt Rettig University Of California Jonsson Comprehensive Cancer Center David Geffen School Of Medicine
Source: wallstreet-online.de